Inhibiting insulin resistance mechanisms by DTS phytocompound: an experimental study on metabolic syndrome-prone adipocytes

Acta Biomed. 2012 Aug;83(2):95-102.

Abstract

The present study was designed to determine whether DTS a phytocompound endowed with antioxidant properties, could beneficially modulate nitric oxide (NO) production stimulated by lipopolysaccharide (LPS) and tumor necrosis factor-alpha (TNF-alpha) in adipocytes. Combined stimulation (CS-treatment) exerted by using 5 microg/ml of LPS together with 100 ng/ml of TNF-alpha significantly enhanced NO production in 3T3-L1 adipocytes. Preincubation of the adipocytes with DTS (10-30 mM) inhibited such phenomenon in a dose-dependent fashion. The production of NO was decreased by 52% at the concentration of 30mM of DTS. The decrease in NO production by DTS was associated also with a decrease in inducible nitric oxide synthase (iNOS) protein and iNOS mRNA expression. Nuclear factor-kappa B (NF-kappaB) was significantly enhanced by CS-treatment, while the pretreatment with 30 mM of DTS prevented the activity by 27%. IL-6 production in 3T3-L1 adipocytes was markedly increased by CS stimulus, and the enhanced secretion of IL-6 was suppressed in a dose-dependent manner by DTS. These results suggest that DTS regulates iNOS expression and NO production in adipocytes through the modulating activation of NF-kappaB and may have a potential clinical application within protocols designed for treating metabolic syndrome. (www.actabiomedica.it).

Publication types

  • Comparative Study

MeSH terms

  • Adipocytes / metabolism*
  • Adipocytes / pathology
  • Cells, Cultured
  • Humans
  • Insulin Resistance*
  • Metabolic Syndrome / drug therapy
  • Metabolic Syndrome / metabolism*
  • Metabolic Syndrome / pathology
  • NF-kappa B / biosynthesis
  • NF-kappa B / drug effects
  • Nitric Oxide / biosynthesis*
  • Nitric Oxide Synthase Type II / biosynthesis
  • Nitric Oxide Synthase Type II / drug effects*
  • Oxidative Stress / drug effects*
  • Sulfonamides / pharmacology*
  • Thiadiazoles / pharmacology*

Substances

  • 2-(2,2-dichloroacetylamino)-1,3,4-thiadiazole-5-sulfonamide
  • NF-kappa B
  • Sulfonamides
  • Thiadiazoles
  • Nitric Oxide
  • Nitric Oxide Synthase Type II